Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680634 | 1.00 | HTR6 (0.44) | HTR6HTR1AHTR7DRD2HTR2A | |
| SCHEMBL20696778 | 0.90 | HTR6 (0.44) | HTR6HTR1ASCN9AKHK | |
| SCHEMBL20696879 | 0.87 | SCN9A (0.35) | SCN9A | |
| SCHEMBL20740778 | 0.87 | HTR6 (0.43) | HTR6DRD2SCN9A | |
| SCHEMBL29948714 | 0.87 | SCN9A (0.35) | SCN9A | |
| SCHEMBL28386063 | 0.86 | HTR6 (0.35) | HTR6DRD2SCN9AKHK | |
| SCHEMBL30534843 | 0.83 | SCN9A (0.39) | SCN9A | |
| SCHEMBL20697136 | 0.83 | SCN9A (0.39) | SCN9A | |
| SCHEMBL20740768 | 0.82 | HTR6 (0.43) | HTR6SCN9A | |
| SCHEMBL30534840 | 0.82 | HTR6 (0.43) | HTR6SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| EP-3658546-B1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-10-26 | — | — | EP | claimed |
| CN-110997654-B | Indole derivatives and uses thereof | 诺华股份有限公司 | 2023-08-15 | — | — | CN | disclosed |